← Leaderboards
David Allen Wilcox
Medical College Of Wisconsin
$6,145,617
Attributed
$10,516,716
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,516,716 · 2
By mechanism
R01$10,516,716 · 2
Top collaborators
- Mary Eapen3 shared
- Parameswaran N Hari2 shared
- Shawn M. Jobe1 shared
Most similar at Medical College Of Wisconsin
Same institution · by research overlap
- Qizhen Shi$6,437,223
- Mary Eapen$20,614,610
- Joan C Gill$1,703,320
- Bryon Duane Johnson$4,264,710
- Parameswaran N Hari$2,110,213
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyHematopoietic Stem CellsMegakaryocytesImmuneAutologousHemostatic FunctionInheritedFactor ViiiCellsCd34 GeneBlood PlateletsGene Transfer VectorHemophilia AHemorrhageBlood VesselsAnimal ModelAnimalsBone MarrowAffectCanis FamiliarisConditioningGenesGene TransferLentivirus Vector
Grant awards (13)
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,577,015
R01 · FY2023 · HL · contact PI
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,589,707
R01 · FY2022 · HL · contact PI
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,613,689
R01 · FY2021 · HL · contact PI
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,596,167
R01 · FY2020 · HL · contact PI
A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies$1,774,215
R01 · FY2019 · HL · contact PI
Therapeutic-Expression of a Platelet-Specific Integrin$338,038
R01 · FY2010 · HL · contact PI
Therapeutic-Expression of a Platelet-Specific Integrin$338,106
R01 · FY2009 · HL · contact PI
Therapeutic-Expression of a Platelet-Specific Integrin$338,170
R01 · FY2008 · HL · contact PI
Therapeutic-Expression of a Platelet-Specific Integrin$351,109
R01 · FY2007 · HL · contact PI
Therapeutic Expression of a Platelet-Specific Integrin$247,000
R01 · FY2005 · HL
Therapeutic Expression of a Platelet-Specific Integrin$247,000
R01 · FY2004 · HL
Therapeutic Expression of a Platelet-Specific Integrin$247,000
R01 · FY2003 · HL
Therapeutic Expression of a Platelet-Specific Integrin$259,500
R01 · FY2002 · HL